- recruitingPHASE3
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
This study is looking at the safety of a new patch treatment, called Viaskin Peanut Patch (DBV712), for peanut allergy in very young children (1 to 3 years old). It aims to see if the patch is safe over six months, with some children receiving the patch and others a dummy patch.
United States · Australia · Canada - ongoing, recruitingTherapeutic use (Phase IV)
A single-centre, randomized, double blind, placebo controlled, crossover, single dose clinical trial to compare orodispersible presentations of bilastine, ebastine, and desloratadine in the suppression of wheal and flare induced by intradermal histamine in healthy volunteers.
This study looks at how quickly different allergy medications in a fast-dissolving form start to work. Researchers will give healthy volunteers a small amount of an irritating substance on their skin and then see how well the medications reduce the resulting redness and swelling compared to a dummy pill.
Spain